Literature DB >> 28181636

C-reactive protein is associated with disability independently of vascular events: the Northern Manhattan Study.

Mandip S Dhamoon1, Ying-Kuen Cheung2, Yeseon P Moon2, Clinton B Wright3, Joshua Z Willey4, Ralph Sacco5, Mitchell Sv Elkind4.   

Abstract

Background: High-sensitivity C-reactive protein (CRP) has been associated with cardiovascular events and mortality, but the association of CRP with functional status is not well defined. We hypothesised that serum levels of high-sensitivity CRP are associated with long-term trajectories of functional status independently of vascular risk factors and stroke and myocardial infarction (MI) occurring during follow-up. Design: Prospective, population-based. Setting: Northern Manhattan Study. Participants: Stroke-free participants aged ≥40 years. Measurements: Annual assessments of disability with the Barthel index (BI) for a median of 13 years. BI was analysed as a continuous variable (range 0–100). Baseline demographics, risk factors and laboratory studies were collected, including CRP (n = 2,240). Separate generalised estimating equation models estimated standardised associations between CRP and (i) baseline functional status and (ii) change in function over time, adjusting for demographics, vascular risk factors, social variables, cognition, and depression measured at baseline, and stroke and MI occurring during follow-up.
Results: Mean age was 69 (SD 10) years, 36% were male, 55% Hispanic, 75% hypertensive and 21% diabetic; 337 MIs and 369 first strokes occurred during follow-up. Mean CRP level was 5.24 mg/l (SD 8.86). logCRP was associated with baseline BI (−0.34 BI points per unit logCRP, 95% confidence interval −0.62, −0.06) but not with change over time. Conclusions: In this large population-based study, higher serum CRP levels were associated with higher baseline disability, even when adjusting for baseline covariates and stroke and MI occurring during follow-up. Systemic inflammation may contribute to disability independently of clinical vascular events.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28181636      PMCID: PMC6075195          DOI: 10.1093/ageing/afw179

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  31 in total

1.  Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study.

Authors:  Ralph L Sacco; Kishlay Anand; Hye-Seung Lee; Bernadette Boden-Albala; Sally Stabler; Robert Allen; Myunghee C Paik
Journal:  Stroke       Date:  2004-09-02       Impact factor: 7.914

2.  Reliability of the activities of daily living scale and its use in telephone interview.

Authors:  D Shinar; C R Gross; K S Bronstein; E E Licata-Gehr; D T Eden; A R Cabrera; I G Fishman; A A Roth; J A Barwick; S C Kunitz
Journal:  Arch Phys Med Rehabil       Date:  1987-10       Impact factor: 3.966

3.  Predictive value of C-reactive protein for the outcome after primary intracerebral hemorrhage.

Authors:  Pekka Löppönen; Cheng Qian; Sami Tetri; Seppo Juvela; Juha Huhtakangas; Michaela K Bode; Matti Hillbom
Journal:  J Neurosurg       Date:  2014-08-29       Impact factor: 5.115

4.  High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study.

Authors:  M S V Elkind; J M Luna; Y P Moon; K M Liu; S L Spitalnik; M C Paik; R L Sacco
Journal:  Neurology       Date:  2009-10-20       Impact factor: 9.910

5.  Stroke rehabilitation: analysis of repeated Barthel index measures.

Authors:  C V Granger; L S Dewis; N C Peters; C C Sherwood; J E Barrett
Journal:  Arch Phys Med Rehabil       Date:  1979-01       Impact factor: 3.966

6.  The behavioral risk factor surveys: II. Design, methods, and estimates from combined state data.

Authors:  E M Gentry; W D Kalsbeek; G C Hogelin; J T Jones; K L Gaines; M R Forman; J S Marks; F L Trowbridge
Journal:  Am J Prev Med       Date:  1985 Nov-Dec       Impact factor: 5.043

7.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

Review 8.  High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.

Authors:  Wolfgang Koenig
Journal:  Int J Cardiol       Date:  2013-08-24       Impact factor: 4.164

9.  Cross-sectional associations of albuminuria and C-reactive protein with functional disability in older adults with diabetes.

Authors:  Hsu-Ko Kuo; Soham Al Snih; Yong-Fang Kuo; Mukaila A Raji
Journal:  Diabetes Care       Date:  2011-02-07       Impact factor: 19.112

10.  Moderate alcohol consumption reduces risk of ischemic stroke: the Northern Manhattan Study.

Authors:  Mitchell S V Elkind; Robert Sciacca; Bernadette Boden-Albala; Tanja Rundek; Myunghee C Paik; Ralph L Sacco
Journal:  Stroke       Date:  2005-11-23       Impact factor: 7.914

View more
  1 in total

1.  Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories.

Authors:  Mandip S Dhamoon; Ying-Kuen Cheung; Yeseon P Moon; Clinton B Wright; Ralph L Sacco; Mitchell S V Elkind
Journal:  PLoS One       Date:  2019-04-01       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.